Seamless monotherapy-combination phase I dose-escalation model-based design
Clinical Trials · 2025
DOI: 10.1177/17407745251350604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Libby Daniells und 6 weiteren Autor:innen. Beteiligte Einrichtung: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Research Design, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIHR Advanced Fellowship.
Abstract (Originalsprache)
Phase I dose-escalation studies for a single-agent and combination of anti-cancer agents have explored various model-based designs to guide identification of a maximum tolerated dose and recommended phase II dose. This work describes a parallel approach to dose escalation to expedite identification of maximum tolerated doses both for an anti-cancer agent as monotherapy and in combination with another agent. We develop a three-parameter Bayesian logistic regression model that allows for more efficient use of information between monotherapy and combination parts of the study. The model allows the monotherapy and combination data to drive dose escalation of the combination of treatments, reflecting the known dose-toxicity relationship between the monotherapy and combination setting. Through a thorough simulation study in which the proposed model is compared to two comparative approaches, the three-parameter Bayesian logistic regression model is shown to accurately select doses in the target toxicity interval, performing similar to comparative approaches in terms of proportion of target dose/combination selection, while more than halving the proportion of doses selected that were greater than the target toxicity, thereby improving safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
- Faculty of Informatics and Data Science, University of Regensburg, Regensburg, Germany.
- Clinical Trials Unit, Cancer Theme, University of Cambridge, Cambridge, UK.
- Department of Oncology, University of Cambridge, Cambridge, UK.
- Edinburgh Experimental Cancer Medicine Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
- Centre for Drug Development, Cancer Research UK, London, UK.
ORCID-Profile: Libby Daniells, Alimu Dayimu, Stefan Symeonides, Pavel Mozgunov
Förderung
- Medical Research Council
- NIHR Advanced Fellowship
Zitieren
APA
Daniells, L., Jaki, T., Dayimu, A., Demiris, N., Bristi, B., Symeonides, S., & Mozgunov, P. (2025). Seamless monotherapy-combination phase I dose-escalation model-based design. Clinical Trials. https://doi.org/10.1177/17407745251350604
Vancouver
Daniells L, Jaki T, Dayimu A, Demiris N, Bristi B, Symeonides S, et al. Seamless monotherapy-combination phase I dose-escalation model-based design. Clinical Trials. 2025. doi:10.1177/17407745251350604
BibTeX
@article{Daniells2025,
author = {Daniells, Libby and Jaki, Thomas and Dayimu, Alimu and Demiris, Nikos and Bristi, Basu and Symeonides, Stefan and Mozgunov, Pavel},
title = {Seamless monotherapy-combination phase I dose-escalation model-based design},
journal = {Clinical Trials},
year = {2025},
doi = {10.1177/17407745251350604}
}
EUVIMED